Infectex has become a resident of the Skolkovo Foundation

A biotech company Infectex is the second portfolio company of Maxwell Biotech Venture Fund to receive the resident status in the Innovation Center of the Skolkovo Foundation.

Infectex, Ltd. is a Russian innovative company, a member of the biotech holding Maxwell Biotech Group. The main activity of Infectex is aimed at development and market promotion of an innovative drug for treatment of multi-drug resistant tuberculosis.

“We are very happy that our cooperation with Skolkovo is developing so actively, – says Dmitry Popov, Managing Partner of Maxwell Biotech Venture Fund. – The drug, that is developed by Infectex, seem to be of a great importance for the Russian healthcare, since it is aimed at the solution of a complicated medical and social problem and suggests serious economic effect”.

The basis for the new drug is the development of an American biotech company Sequella, acting as the project partner. The drug candidate represents a low-molecular compound of ethylendiamine class; some of the family members are actively used in the tuberculosis front-line therapy. So, for example, ethambutol – a compound of the same class – is recommended for tuberculosis therapy by the World Healthcare Organization.

In the opinion of Russian and international experts, introduction of a new antitubercular agent, designed by Infectex, to the Russian market will expand the possibilities for treatment of patients with multi-drug resistant form of tuberculosis, by ensuring efficiency upgrade, reduction of therapy timeframes and decrease in causal treatment adverse effects rate.


Anna Zelenkova,
PR manager at Maxwell Biotech Group;
Tel.: +7 (495) 411-6992